Are you living with Type 1 Diabetes? You may have the opportunity to participate in a Phase II clinical study evaluating a non-surgical insulin delivery device.

The study involves a co-formulated insulin product containing long-acting basal insulin and rapid-acting insulin. The study is designed to evaluate the treatment over several phases:

Screening & Lead-In: Approximately 2 weeks

Treatment Period: 16 weeks

Safety Follow-Up: 2 weeks

If you are interested in learning more about this study and whether you may qualify, contact our research team to learn more about participation and eligibility requirements.